Restless legs syndrome (RLS) and periodic limb movements in sleep (PLM
S) are disorders that are common and disturbing to uremic patients. Th
e treatment of these is problematic. Eight patients on chronic hemodia
lysis and continuous peritoneal dialysis completed a double-blind plac
ebo-controlled crossover study using incremental doses of pergolide up
to 0.25 mg at bedtime for treatment of RLS and sleep disruption. Five
patients (62.5%) noted subjective improvement in restless legs sympto
ms and sleep quality. Objective results were improved only slightly by
treatment. The percentage of the first hour in bed during which leg m
ovements occurred decreased from 20.5+/-6.0 to 11.5+/-3.3, p<0.05. How
ever, findings during sleep were less positive. The following measures
were not significant between placebo and treatment: leg movements per
hour of sleep [53.7+/-22.3 vs 35.8+/-11.8 (p=0.2)]; and percentage of
sleep time spent with leg movements [5.5%+/-3.2 vs 4.4%+/-1.4 (p=0.37
)], Patients continued to have very disrupted sleep, and we could not
document an objective improvement in sleep architecture. Thus, althoug
h pergolide at the dose of 0.25 mg at bedtime provided subjective impr
ovement in symptoms of restless legs and quality of sleep, and objecti
vely decreased leg movements during the first hour in bed, objectively
sleep continued to be disrupted. In this small patient group, the res
ponse to pergolide was not uniform, and further investigation is requi
red to test effectiveness at higher doses.